Back to top

Image: Bigstock

NAII Stock Declines as Weak Manufacturing Demand Affects Q1 Earnings

Read MoreHide Full Article

Shares of Natural Alternatives International, Inc. (NAII - Free Report) have fallen 5.3% since the company reported its first-quarter fiscal 2027 earnings compared with the S&P 500’s 3.6% decline over the same period. Over the past month, the stock has lost 24.4%, underperforming the S&P 500’s 6.1% decrease.

Natural Alternatives reported net sales of $28.1 million for the quarter ended Sept. 30, 2026, corresponding to the first quarter of fiscal 2027, down 25.5% from $37.7 million in the year-ago period. The company incurred a net loss of $2.5 million, or 41 cents per share, compared with a loss of $0.3 million, or 5 cents per share, a year earlier. The deterioration primarily reflected weaker contract manufacturing demand and reduced factory utilization.

NAII's Segment Performance

Private-label contract manufacturing revenues declined 29.1% to $25.6 million from $36.1 million a year earlier. The drop reflected reduced orders from several major customers, partly associated with excess inventories and delayed product launches. New customer product launches partially offset the decline.

Patent and trademark licensing revenues, including CarnoSyn beta-alanine royalties, licensing and raw material sales, increased 54% to $2.6 million from $1.7 million. Higher TriBsyn product sales supported growth, partially offset by lower instant-release CarnoSyn raw material sales.

The largest private-label contract manufacturing customer accounted for 29% of consolidated sales compared with 38% in the prior-year quarter.

NAII's Profitability and Operating Expenses

Gross profit declined 71% to $1.3 million from $4.4 million in the year-ago quarter. Gross margin contracted to 4.5% from 11.7%, primarily reflecting lower manufacturing volumes and underutilized production capacity.

The contract manufacturing segment recorded a gross loss of $0.7 million compared to a gross profit of $3.2 million previously. Conversely, licensing gross profit increased to $1.9 million from $1.2 million.

Selling, general and administrative expenses declined 6% to $3.8 million, primarily due to lower employee compensation expenses associated with reduced headcount. However, costs related to preparing the corporate office for sale partly offset these savings.

The company reported an operating loss of $2.6 million against operating income of $0.3 million a year earlier. Other net expenses declined to $0.2 million from $0.5 million, benefiting from favorable foreign exchange activity, partially offset by higher interest expenses.

NAII's Liquidity Position

Operating activities generated $1.2 million in cash compared with cash utilization of $4 million in the prior-year period. Changes in accounts receivable and inventory supported cash generation.

Cash, cash equivalents and restricted cash totaled $6.7 million as of Sept. 30, 2026 compared with $7.5 million on June 30, 2026. Working capital declined to $14.7 million from $27.7 million.

Outstanding credit-line borrowings totaled $6.3 million, with $11.8 million in borrowing capacity available. The company also reported $10.8 million outstanding on its real estate term loan.

NAII disclosed noncompliance with a financial covenant under its domestic credit agreement. Consequently, certain previously long-term borrowings were reclassified as current liabilities. Management is discussing potential remedies with its lender.

NAII: Management Commentary and Outlook

Chairman and CEO Mark A. LeDoux characterized the quarterly results as disappointing but indicated that customer reluctance to fulfill forecast commitments had begun to ease.

Management highlighted encouraging discussions with existing and prospective customers and expanded research into combinations of CarnoSyn and popular peptides.

The company anticipates higher net sales in fiscal 2027 compared with fiscal 2026 and expects to return to profitability in the fourth quarter of fiscal 2027. However, these expectations remain dependent on recovering customer demand and improving manufacturing utilization.

Other Developments at NAII

Natural Alternatives consolidated most U.S. production operations into its Vista, CA, manufacturing facility and initiated the process of selling its Carlsbad manufacturing facility to reduce operating costs and improve efficiency.

The company also initiated a comprehensive strategic alternatives review, including potential mergers, acquisitions, joint ventures or a sale of the company.

Published in